Median Technologies, a France-based developer of artificial intelligence-powered software as a medical device, has entered a non-exclusive distribution agreement with Tempus AI, Inc. to commercialise its Eyonis LCS lung screening platform in the United States. The collaboration follows regulatory clearance and is focused on integrating the software-based medical device into high-volume clinical imaging workflows through Tempus’ Pixel platform.

Under the agreement, Tempus AI will distribute Eyonis LCS to imaging providers nationwide while managing onboarding, system integration, and workflow deployment. The partnership is intended to scale adoption of advanced diagnostic software that enhances detection and characterisation of lung abnormalities using low-dose CT imaging.

Tempus Pixel is a US Food and Drug Administration-cleared and CE-marked artificial intelligence-enabled radiology platform that provides automated image analysis and reporting tools. The platform is designed to support data-driven diagnostic workflows, enabling providers to quantify lesions and standardise imaging interpretation.

Eyonis LCS — an artificial intelligence-based CADe/CADx software as a medical device — recently received US Food and Drug Administration 510(k) clearance. The system analyses low-dose CT scans and has demonstrated manufacturer-reported performance metrics of 93.3 percent sensitivity, 92.4 percent specificity, and 99.9 percent negative predictive value, supporting earlier identification of suspicious findings and more consistent screening processes.

Company executives said the collaboration is aimed at enabling large-scale deployment of regulated imaging software across the US market. Revenues generated from Eyonis LCS will be shared under agreed commercial terms. The partnership also aligns with an established NT-APC reimbursement pathway valued between USD 601 and USD 700 and targets approximately 14.5 million Americans eligible for lung cancer screening.

Median is progressing along the European regulatory pathway for Eyonis LCS and expects CE marking in the second quarter of 2026. The distribution agreement includes provisions for Tempus AI to support commercial rollout in Europe once approval is secured.

Median Technologies specialises in artificial intelligence-driven software platforms and imaging services that support oncology research and early disease detection, helping standardise diagnostic workflows and accelerate adoption of regulated medical device technologies.

If you want, I can make the tone more industrial, regulatory-focused, or manufacturing-supply-chain oriented.